Second-quarter sales rose 31.2 percent and net income jumped 20.7 percent for Illumina Inc. (NSDQ:ILMN), even as the company announced its plans to get into the bench-top polymerase chain reaction business with the acquisition of Helixis Inc.
The San Diego-based genetic lab instruments maker reported net income of $29.8 million, or 21 cents per diluted share, on sales of $212.0 million during the three months ended July 4. That compares with net income of $24.7 million, or 18 cents per diluted share, on sales of $161.6 million during the three months ended June 28, 2009.